UA109290C2 - Спільні кристали і солі інгібіторів ccr3 - Google Patents

Спільні кристали і солі інгібіторів ccr3

Info

Publication number
UA109290C2
UA109290C2 UAA201305572A UAA201305572A UA109290C2 UA 109290 C2 UA109290 C2 UA 109290C2 UA A201305572 A UAA201305572 A UA A201305572A UA A201305572 A UAA201305572 A UA A201305572A UA 109290 C2 UA109290 C2 UA 109290C2
Authority
UA
Ukraine
Prior art keywords
salts
common crystals
ccr3 inhibitors
ccr3
inhibitors
Prior art date
Application number
UAA201305572A
Other languages
English (en)
Ukrainian (uk)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of UA109290C2 publication Critical patent/UA109290C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
UAA201305572A 2010-10-07 2011-06-10 Спільні кристали і солі інгібіторів ccr3 UA109290C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10186901 2010-10-07
PCT/EP2011/067437 WO2012045803A1 (en) 2010-10-07 2011-10-06 Co-crystals and salts of ccr3-inhibitors

Publications (1)

Publication Number Publication Date
UA109290C2 true UA109290C2 (uk) 2015-08-10

Family

ID=44741339

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201305572A UA109290C2 (uk) 2010-10-07 2011-06-10 Спільні кристали і солі інгібіторів ccr3

Country Status (36)

Country Link
US (3) US8742115B2 (ru)
EP (1) EP2625174B1 (ru)
JP (1) JP5794713B2 (ru)
KR (3) KR101844215B1 (ru)
CN (1) CN103140486B (ru)
AP (1) AP3268A (ru)
AR (1) AR083353A1 (ru)
AU (1) AU2011311530B2 (ru)
BR (2) BR122021010665B1 (ru)
CA (1) CA2807255C (ru)
CL (1) CL2013000488A1 (ru)
CO (1) CO6710910A2 (ru)
CY (1) CY1116168T1 (ru)
DK (1) DK2625174T3 (ru)
EA (1) EA029097B1 (ru)
EC (1) ECSP13012600A (ru)
ES (1) ES2535264T3 (ru)
GE (1) GEP20166488B (ru)
HR (1) HRP20150419T1 (ru)
HU (1) HUE024540T2 (ru)
IL (1) IL224269A (ru)
MA (1) MA34545B1 (ru)
ME (1) ME02040B (ru)
MX (1) MX2013003785A (ru)
MY (1) MY167898A (ru)
NZ (1) NZ605827A (ru)
PE (1) PE20140188A1 (ru)
PL (1) PL2625174T3 (ru)
PT (1) PT2625174E (ru)
RS (1) RS53858B1 (ru)
SG (1) SG188949A1 (ru)
SI (1) SI2625174T1 (ru)
TW (1) TWI546294B (ru)
UA (1) UA109290C2 (ru)
UY (1) UY33655A (ru)
WO (1) WO2012045803A1 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
UA109290C2 (uk) * 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
AR090566A1 (es) * 2012-04-02 2014-11-19 Boehringer Ingelheim Int Proceso para la produccion de inhibidores de crr
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) * 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
US20200054622A1 (en) * 2017-04-05 2020-02-20 Alkahest, Inc. Methods and Compositions for Treating Aging-Associated Impairments Using CCR3-Inhibitors
WO2018187473A1 (en) 2017-04-05 2018-10-11 Alkahest Inc. Methods and compositions for treating retina-associated disease using ccr3-inhibitors
EP3606525A4 (en) * 2017-04-05 2020-09-09 Alkahest, Inc. METHODS AND COMPOSITIONS FOR TREATING AGING-ASSOCIATED DISORDERS USING CCR3 INHIBITORS
JP2020536929A (ja) * 2017-10-13 2020-12-17 アルカヘスト,インコーポレイテッド Ccr3阻害剤を用いた、そう痒症、乾皮症、及び関連疾患を治療するための方法及び組成物
SG11202010115RA (en) 2018-05-15 2020-11-27 Alkahest Inc Treatment of aging-associated disease with modulators of leukotriene a4 hydrolase
CN112789044A (zh) * 2018-09-26 2021-05-11 万能溶剂有限公司 使用ccr3-抑制剂治疗衰老相关损伤的方法及组合物
AU2022376563A1 (en) 2021-11-01 2023-12-07 Alkahest, Inc. Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7907121L (sv) 1979-08-27 1981-02-28 Astra Laekemedel Ab Ftalimidinderivat
JP2807577B2 (ja) 1990-06-15 1998-10-08 エーザイ株式会社 環状アミド誘導体
US6433165B1 (en) 1998-01-21 2002-08-13 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
WO1999038514A1 (en) 1998-02-02 1999-08-05 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
US6140349A (en) 1998-02-02 2000-10-31 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
US6936718B2 (en) 2001-11-29 2005-08-30 Schering Corporation Preparation of rotamer mixtures of pharmaceutical salts
EP1596869B1 (en) 2003-01-21 2014-06-04 New Form Pharmaceuticals Inc. Novel cocrystallization
CA2543419A1 (en) 2003-10-24 2005-05-06 Leyi Gong Ccr3 receptor antagonists
ATE428422T1 (de) 2004-02-05 2009-05-15 Schering Corp Piperidin-derivate als ccr3-antagonisten
WO2006007448A2 (en) 2004-06-17 2006-01-19 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions and related methods of use
JP2006137718A (ja) 2004-11-12 2006-06-01 Astellas Pharma Inc インドール若しくはインダゾール誘導体
WO2006083390A2 (en) 2004-12-07 2006-08-10 Children's Hospital Medical Center Eotaxin-3 in eosinophilic esophagitis
DOP2006000051A (es) 2005-02-24 2006-08-31 Lilly Co Eli Inhibidores de vegf-r2 y métodos
JP3701964B1 (ja) * 2005-03-08 2005-10-05 アステラス製薬株式会社 キヌクリジン誘導体の新規な塩
US20090124636A1 (en) * 2006-04-12 2009-05-14 Pfizer Inc. Chemical compounds
DE602007008222D1 (de) 2006-04-20 2010-09-16 Hoffmann La Roche Diazepanderivate als modulatoren von chemokinrezeptoren
GB0701992D0 (en) 2007-02-02 2007-03-14 7Tm Pharma As Grehlin Receptor Modulators
US8008092B2 (en) 2007-10-09 2011-08-30 University Of Kentucky Research Foundation CCR3 inhibition for ocular angiogenesis and macular degeneration
TW201000446A (en) 2008-05-30 2010-01-01 Astrazeneca Ab New compounds useful in pain therapy
US8278302B2 (en) * 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
UA109290C2 (uk) * 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
AR090566A1 (es) 2012-04-02 2014-11-19 Boehringer Ingelheim Int Proceso para la produccion de inhibidores de crr
US20130261153A1 (en) 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists

Also Published As

Publication number Publication date
CA2807255A1 (en) 2012-04-12
JP5794713B2 (ja) 2015-10-14
US20150105371A1 (en) 2015-04-16
SG188949A1 (en) 2013-05-31
MX2013003785A (es) 2013-06-05
JP2013542207A (ja) 2013-11-21
BR112013008211A8 (pt) 2017-10-10
EP2625174B1 (en) 2015-01-21
CN103140486A (zh) 2013-06-05
EA201300436A1 (ru) 2013-08-30
AP3268A (en) 2015-05-31
ME02040B (me) 2015-05-20
GEP20166488B (en) 2016-06-10
IL224269A (en) 2017-08-31
CY1116168T1 (el) 2017-02-08
KR20190104645A (ko) 2019-09-10
NZ605827A (en) 2015-09-25
CL2013000488A1 (es) 2013-07-05
HRP20150419T1 (hr) 2015-05-22
CO6710910A2 (es) 2013-07-15
CN103140486B (zh) 2016-08-03
KR101844215B1 (ko) 2018-04-03
PT2625174E (pt) 2015-03-09
TWI546294B (zh) 2016-08-21
BR112013008211B1 (pt) 2021-08-24
US20140135307A1 (en) 2014-05-15
MA34545B1 (fr) 2013-09-02
HUE024540T2 (hu) 2016-01-28
EA201300436A8 (ru) 2018-01-31
BR122021010665B1 (pt) 2022-03-15
PE20140188A1 (es) 2014-02-26
US8742115B2 (en) 2014-06-03
TW201305134A (zh) 2013-02-01
WO2012045803A1 (en) 2012-04-12
MY167898A (en) 2018-09-26
CA2807255C (en) 2018-11-13
KR102239690B1 (ko) 2021-04-13
KR20130118313A (ko) 2013-10-29
AU2011311530B2 (en) 2015-04-09
US20120264729A1 (en) 2012-10-18
AU2011311530A1 (en) 2013-01-31
KR102163874B1 (ko) 2020-10-12
KR20180005717A (ko) 2018-01-16
AP2013006679A0 (en) 2013-01-31
RS53858B1 (en) 2015-08-31
BR112013008211A2 (pt) 2016-06-21
EP2625174A1 (en) 2013-08-14
SI2625174T1 (sl) 2015-03-31
AR083353A1 (es) 2013-02-21
PL2625174T3 (pl) 2015-06-30
DK2625174T3 (da) 2015-02-02
UY33655A (es) 2012-04-30
EA029097B1 (ru) 2018-02-28
ES2535264T3 (es) 2015-05-07
US9233950B2 (en) 2016-01-12
ECSP13012600A (es) 2013-07-31

Similar Documents

Publication Publication Date Title
UA109290C2 (uk) Спільні кристали і солі інгібіторів ccr3
PH12017501306A1 (en) Inhibitors of histone demethylases
MX348422B (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
EA201300684A1 (ru) Производные 6-амино-2-фениламино-1н-бензимидазол-5-карбоксамида и их применение в качестве ингибиторов микросомной простагландин-е2-синтазы-1
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
NZ708593A (en) Novel pyrazole derivative
EA201290191A1 (ru) N1-ПИРАЗОЛОСПИРОКЕТОНОВЫЕ ИНГИБИТОРЫ АЦЕТИЛ-KoA-КАРБОКСИЛАЗЫ
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
UA110943C2 (ru) N-ацилсульфонамидные промоторы апоптоза
MX2013004491A (es) Boronatos como inhibidores de arginasa.
ECSP12012326A (es) Derivados de aminopirimidina como moduladores de la lrrk2
BR112012007747A2 (pt) Compostos heterocíclicos úteis como inibidores de pdk1, sua composição farmacêutica e seus usos
JO3007B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
EA201290184A1 (ru) Бензодиазепиновый ингибитор бромодомена
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
EA201201192A1 (ru) Тиенопиримидины, содержащие замещенную алкильную группу, предназначенные для фармацевтических композиций
EA201390163A1 (ru) Гетеробициклические производные в качетстве ингибиторов hcv
MX2011009847A (es) Agentes antihelminticos y su uso.
UA112055C2 (uk) Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений
BR112014001908A2 (pt) derivados aza heterocíclicos substituídos
MX340033B (es) Derivados heterobiciclicos como inhibidores del virus de la hepatitis c.
MX2011013869A (es) Agentes antihelminticos y su uso.
EA201290229A1 (ru) Производные спиролактама и их применение
MX348127B (es) Derivados de quinazolinona como inhibidores del virus de la hepatitis c.